Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid) – A double-blind, randomised, multicentre study in adults

Kłęk, Stanisław; Chambrier, C.; Singer, Pierre; Rubin, M.; Bowling, Tim; Staun, Michael; Joly, Francisca; Rasmussen, Henrik Højgaard; Strauss, Boyd Josef Gimnicher; Wanten, Geert; Smith, Ross C.; Abraham, Arun; Szczepanek, Kinga; Shaffer, Jon

doi:10.1016/j.clnu.2012.06.011

Cited by 115 publications

(187 citation statements)

References 36 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…Most of the studies were focused on middle-aged surgical or critically ill patients. Seven (44%) of the 16 studies found some positive results for LETs or liver ultrasound tests in patients receiving IVLEs containing FO (8,11,12,15,16,19,21). Studies using FO in doses of ≥ 0.150 mg/kg/day presented more positive results than those with lower doses.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

“…Four (50%) of the eight studies using this IVLE resulted in positive outcomes (8,11,16,21). The second most studied IVLE is an emulsion containing SO 40%, MCT 50%, and FO 10%.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

“…Several prospective studies have been published assessing the preventive effect of IVLEs containing FO on alterations in LETs or PNALD (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Characteristics of these studies are shown in table I.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

“…This lapse could be shorter than the usual PN course in clinical settings. Only one study had a four-week duration, resulting in an improved LET using a multicomponent oil emulsion containing FO 15% in doses of > 0.150 g/kg/day (16). Another important limitation is the age of the patients under assessment, who were younger than many patients requiring PN nowadays, usually older than 70.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

See 3 more Smart Citations

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Joaquín¹,

Florit-Sureda²

2017

Nutr Hosp

View full text Add to dashboard Cite

Mateu-de-Antonio J, Florit-Sureda M. Effects unrelated to anti-infl ammation of lipid emulsions containing fi sh oil in parenteral nutrition for adult patients. Nutr Hosp 2017;34:193-203 ResumenSe han publicado varias revisiones y metaanálisis sobre la modulación de las respuestas infl amatorias e inmunológicas por la administración de ácidos grasos poliinsaturados (AGPI) omega-3. Sin embargo, los AGPI omega-3 ejercen otras acciones no directamente relacionadas con estas respuestas. El objetivo de este trabajo es revisar los efectos de las emulsiones lipídicas intravenosas (ELIV) que contienen aceite de pescado (AP) en la nutrición parenteral (NP) de pacientes adultos. Estas emulsiones pueden tener un papel importante en la prevención de las alteraciones del perfi l hepático o de la enfermedad hepática asociada a la NP (EHANP) en comparación con las ELIV sin AP. Los estudios que usaron dosis ≥ 0,150 mg/kg/día presentaron resultados más positivos que aquellos con dosis menores. Una vez se ha presentado la EHANP, el uso de una ELIV compuesta exclusivamente de AP, a dosis de 0,25-1 g de AP/kg/día durante varias semanas, podría atenuar o incluso revertir la alteración hepática y la colestasis cuando la administración de la NP es crónica. Las ELIV con AP parecen tener un aclaramiento plasmático más rápido, lo que podría suponer una ventaja en ciertos pacientes. Algunos estudios también sugieren que estas emulsiones podrían mejorar la función respiratoria. En general, estas ELIV que contienen AP son muy seguras, no aumentan el estrés oxidativo e incluso incrementan el nivel de alfa-tocoferol plasmático. Asimismo, no alteran la sensibilidad a la insulina o el control glicémico y tampoco se ha demostrado que afecten clínicamente a la agregación plaquetaria o a la hemostasia. En conclusión, el uso de ELIV con AP en la NP podría suponer algunas ventajas frente a la ELIV sin AP, además de la modulación de la respuesta infl amatoria sistémica. AbstractSeveral reviews and meta-analyses on modulated infl ammatory and immunologic responses after the administration of omega-3 polyunsaturated fatty acids (PUFAs) in different diseases and conditions have been published. However, omega-3 PUFAs exert several other actions which are not directly related to immunologic or infl ammatory responses. The aim of this paper was to review the effects which are not directly related to immunologic and infl ammatory responses of intravenous lipid emulsions (IVLEs) containing fi sh oil (FO) in parenteral nutrition (PN) for adult patients. IVLEs containing FO could have a role in the prevention of alterations in liver enzyme tests (LETs) or PN-associated liver disease (PNALD). Studies using FO doses of ≥ 0.150 mg/kg/day or IVLEs with high FO concentration reported more positive results than those with lower doses. Once PNALD was developed, the use of IVLEs exclusively composed of FO at doses of 0.25-1 g of FO/kg/day for several weeks could attenuate or even eradicate cholestasis and liver alteration. IVLEs containing FO seemed to have faster...

show abstract

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

“…Four (50%) of the eight studies using this IVLE resulted in positive outcomes (8,11,16,21). The second most studied IVLE is an emulsion containing SO 40%, MCT 50%, and FO 10%.…”

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

Section: Potential Benefits Prevention Of Alterations In Liver Enzymementioning

confidence: 99%

See 2 more Smart Citations

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Joaquín¹,

Florit-Sureda²

2017

Nutr Hosp

View full text Add to dashboard Cite

show abstract

“…The fish oil-supplemented PN resulted in a beneficial alteration in lipid mediator profiles, 94 the clinical significance of which still remains to be confirmed. A third-generation lipid emulsion containing soybean, medium-chain triglyceride, olive and fish oils (SMOFlipid) resulted in favorable FA profiles (a desirable reduction in the ω-6/ω-3-FA ratio) 95 and retained hepatocellular integrity. 96 Small trials showed that fish oil-(ω-3) supplemented PN had anti-inflammatory and hepatoprotective effects in hyperinflammatory disease such as sepsis, 97 a beneficial effect on PN-associated liver disease, 98 reduced the Acute Physiology and Chronic Health Evaluation (APACHE) II and Simplified Acute Physiology Score II, as well as procalcitonin in sepsis.…”

Section: Omega-3 Fatty Acids (Anti-inflammatory Nutrients)mentioning

confidence: 99%

Immunonutrition: a South African perspective

Prins

Visser

2012

South African Journal of Clinical Nutrition

View full text Add to dashboard Cite

Evaluation of the efficacy and safety of a new formulation‐lipid emulsion‐based PTX injection: Pharmacokinetics, tissue distributions and anticancer effect on human gastric cancer cells in vitro

Fei

Wang

et al. 2021

Biomedical Chromatography

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the most widely used chemotherapeutic agents. The commercial PTX formulation was based on Cremophor EL and ethanol owing to its poor aqueous solubility. However, Cremophor EL has been shown to cause toxic effects such as life-threatening anaphylaxis. In our study, we diluted PTX in a commercially available 20% (w/v) lipid emulsion (Lip-PTX) in order to avoid Cremophor EL. The purpose of this study was to evaluate the pharmacokinetics and tissue distributions between Lip-PTX and PTX injection. We also investigated the effects of Lip-PTX and PTX injection on human gastric cancer cells HGC-27 by MTT assay. The apoptosis was detected by flow cytometry with Annexin V/propidium iodide (PI) double staining. Furthermore, the safety such as acute toxicity was also assessed. The results showed that PTX in Sprague-Dawley rats administered Lip-PTX exhibited extended half-life, increased clearance (P < 0.05) and smaller area under the concentrationtime curve compared with PTX injection and there was little significant difference in the distribution of PTX in Sprague-Dawley rats or tumor-bearing mice between Lip-PTX and PTX injection. The cells treated with Lip-PTX had a higher percentage of apoptosis and a higher G 2 /M phase ratio, which indicated that the anticancer effect of Lip-PTX was significantly better than that of PTX injection. Moreover, our study highlighted the safety of Lip-PTX. This study demonstrated the feasibility and potential advantages of Lip-PTX for clinical therapy.

show abstract

Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid) – A double-blind, randomised, multicentre study in adults

Cited by 115 publications

References 36 publications

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

Immunonutrition: a South African perspective

Evaluation of the efficacy and safety of a new formulation‐lipid emulsion‐based PTX injection: Pharmacokinetics, tissue distributions and anticancer effect on human gastric cancer cells in vitro

Contact Info

Product

Resources

About